logo
Plus   Neg
Share

Short-Term Investor Stock FIVN Gains 35.4%

The stock, Five9 Inc. (FIVN), featured on our 'Short-Term Investor' on August 1, 2019, at an opening price of $59.50. On February 19, 2020, the stock touched a new 52-week high of $80.58, representing a gain of 35.4%. The stock closed Wednesday's trade at $78.75.

Why we published this stock?

Five9 Inc. raised its fiscal 2019 guidance, while reporting Q2 results.

Q3, FY19 Guidance

For the third quarter of 2019, Five9 expected revenue in the range of $78.0 million - $79.0 million, GAAP net loss in the range of $6.3 million - $5.3 million, or a loss of $0.10 - $0.09 per basic share, and non-GAAP net income in the range of $8.8 million - $9.8 million, or $0.14 - $0.15 per diluted share.

Wall Street analysts estimated earnings of $0.14 per share on revenue of $75.73 million for the quarter.

For the full year 2019, the company then projected revenue in the range of $312.5 million - $314.5 million, up from the prior guidance range of $304.0 million - $307.0 million that was previously provided on May 1, 2019.

GAAP net loss was expected in the range of $12.0 million - $10.0 million or $0.20 - $0.16 per basic share, improved from the prior guidance range of loss $17.3 million - $14.3 million or $0.29 to $0.24 loss per basic share.

Non-GAAP net income was then expected to be in the range of $44.7 million - $46.7 million or $0.70 - $0.73 per share, up from the prior guidance range of $39.3 million - $42.3 million or $0.61 - $0.66 per share.

Fifteen Wall Street analysts had a consensus earnings estimate of $0.64 per share on revenue of $306.21 million for fiscal 2019.

Q2 Results

GAAP net loss for the second quarter of 2019 was $1.9 million, or $0.03 per basic share, compared to a loss of $2.0 million, or $0.04 per basic share, for the second quarter of 2018.

Non-GAAP net income was $12.3 million, or $0.20 per share, compared to $6.9 million, or $0.11 per share, for the second quarter of 2018.

Revenue for the quarter of 2019 increased 27% to a record $77.4 million, compared to $61.1 million for the second quarter of 2018.

Analysts polled by Thomson Reuters estimated earnings of $0.12 per share on revenue of $77.44 million for the quarter. Analysts' estimate typically exclude certain special items.

Free Sign Up
Free Sign Up

Short-Term Investor Top Perfomers
Pub. DateCompany% Gain
01/10/2018 TNDM + 696.14
05/08/2018 TREX + 211.39
05/17/2016 MIME + 207.12
01/07/2016 QUAD + 198.90
05/24/2016 EXEL + 185.08
08/08/2019 ACMR + 184.92
01/30/2015 CORT + 161.51
01/19/2017 TAL + 149.84
08/20/2015 MSG + 141.43
01/09/2017 EXAS + 140.34
Complete Performance
Under the Radar Top Perfomers
Pub. DateCompany% Gain
04/27/2020 MDGS + 108.50
02/20/2013 IKNX + 99.41
08/13/2014 INGN + 98.42
11/11/2014 CYAN + 89.14
02/22/2019 BOOM + 87.02
12/11/2014 INTL + 86.33
03/07/2019 FLY + 81.83
10/23/2014 OFLX + 81.26
08/14/2014 AMOT + 79.00
02/07/2018 MHH + 78.84
Complete Performance
Emerging Biostocks Top Perfomers
Pub. DateCompany% Gain
04/19/2017 MRTX + 4951
07/17/2018 AMRN + 737
04/05/2017 MYOK + 734
10/03/2019 CNST + 552
02/11/2016 TBRA + 542
11/25/2017 CBIO + 464
09/03/2019 APLT + 437
11/03/2019 THOR + 362
09/21/2018 CCXI + 339
02/05/2018 VKTX + 295
07/01/2020 CRDF + 266
04/24/2020 LVGO + 263
04/16/2020 TFFP + 237
08/06/2019 ZLAB + 225
01/18/2018 ADVM + 218
06/06/2018 CSBR + 216
03/26/2020 MRNA + 216
04/06/2020 TBIO + 184
04/08/2019 SOLY + 170
07/08/2019 PRNB + 152
Complete Performance
Free Sign Up